HLS Therapeutics Inc Share Price Toronto S.E.
Stocks
AM
CA05328X1015
Pharmaceuticals
OTC Markets Traded| Market Cap | 8.26Cr 7.34Cr 6.85Cr 6.25Cr 12Cr 794.48Cr 12Cr 83Cr 32Cr 406.15Cr 31Cr 30Cr 1.3TCr | P/E 2026 * |
-13.1x | P/E 2027 * | -38.8x |
|---|---|---|---|---|---|
| Enterprise Value | 8.26Cr 7.34Cr 6.85Cr 6.25Cr 12Cr 794.48Cr 12Cr 83Cr 32Cr 406.15Cr 31Cr 30Cr 1.3TCr | EV / Sales 2026 * |
1.42x | EV / Sales 2027 * | 1.27x |
| Free-Float |
99.45% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: HLS Therapeutics Inc
| Manager | Title | Age | Since |
|---|---|---|---|
Craig Millian
CEO | Chief Executive Officer | 58 | 01/05/2023 |
John Hanna
DFI | Director of Finance/CFO | 61 | 26/01/2024 |
Jason Gross
CTO | Chief Tech/Sci/R&D Officer | 61 | 01/06/2014 |
| Director | Title | Age | Since |
|---|---|---|---|
Rodney Hill
BRD | Director/Board Member | 58 | 12/03/2018 |
John Welborn
CHM | Chairman | 48 | 22/06/2023 |
Norma Beauchamp
BRD | Director/Board Member | 65 | 01/01/2021 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | -0.41% | - | - | 8.26Cr | |
| -0.61% | -3.43% | +36.07% | +117.61% | 1,01900Cr | |
| -1.02% | -5.60% | +35.72% | +64.82% | 62TCr | |
| +1.11% | -0.58% | +12.36% | +78.27% | 46TCr | |
| +0.34% | -3.01% | +61.79% | +41.79% | 36TCr | |
| -0.95% | -4.05% | +20.54% | +40.33% | 33TCr | |
| -1.46% | -2.89% | +10.57% | +26.54% | 27TCr | |
| -1.35% | -5.43% | -6.17% | +8.82% | 24TCr | |
| -1.04% | -2.79% | +35.30% | +54.42% | 22TCr | |
| -1.87% | -4.10% | +28.44% | +97.54% | 18TCr | |
| Average | -0.68% | -3.39% | +26.07% | +58.90% | 41.08TCr | |
| Weighted average by Cap. | -0.60% | -3.33% | +29.07% | +71.15% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 5.83Cr 5.18Cr 4.84Cr 4.41Cr 8.32Cr 560.82Cr 8.39Cr 59Cr 23Cr 286.7Cr 22Cr 21Cr 920.12Cr | 6.51Cr 5.78Cr 5.4Cr 4.92Cr 9.27Cr 625.43Cr 9.36Cr 65Cr 25Cr 319.73Cr 24Cr 24Cr 1.03TCr |
| Net income | -54.7L -48.6L -45.36L -41.34L -77.97L -53Cr -78.7L -5.49Cr -2.13Cr -27Cr -2.05Cr -2.01Cr -86Cr | -21.64L -19.23L -17.95L -16.36L -30.86L -21Cr -31.14L -2.17Cr -84.17L -11Cr -81.27L -79.5L -34Cr |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
